Evidence check: hsCRP in the context of Wechseljahre

An hsCRP level above 3.0 mg/L indicates elevated cardiovascular risk due to systemic inflammation. During menopause (perimenopause and postmenopause), the natural decline in estrogen can increase inflammatory activity and potentially raise hsCRP. However, hsCRP is a non-specific marker: acute infections, injuries, or chronic inflammatory conditions (e.g., rheumatoid arthritis) must be ruled out before interpreting the result. The evidence here is based on clinical practice, not on menopause-specific studies. Lifestyle interventions—such as a balanced diet, regular exercise, and weight management—are the primary strategies to lower elevated hsCRP. A comprehensive cardiovascular risk assessment (including lipid profile, blood pressure, and fasting glucose) is essential. Hormone therapy may affect hsCRP levels but is not recommended solely for cardiovascular prevention. Caveat: repeat testing and clinical context are needed, as hsCRP can fluctuate significantly.